Mammography Guidelines Just Contradicted Themselves

Tuesday, June 9th, 2026. You're listening to Beyond the Scan — I'm Jackie, and we have a lot to get into today.

This episode is brought to you by RadiologyJobs — the job board built specifically for imaging professionals. Worth bookmarking.

Today we're covering theranostics and the radiopharmaceutical pipeline, what's happening with breast cancer screening guidelines, and a labor story that belongs on every imaging department's radar.

Let's start with something that has been building quietly for years and is now very much not quiet. Theranostics. If you haven't heard the term, it's a contraction of "therapy" and "diagnostics" — and the concept is exactly what it sounds like. You use the same molecular agent to first image a tumor, then treat it. Same target. Different radioisotope attached. See it, treat it.

The FDA has now approved 67 radiopharmaceuticals total — 54 diagnostic, 13 therapeutic. All 13 therapeutic agents are oncology-focused. The two names you're hearing most right now are Lutathera, for neuroendocrine tumors, and Pluvicto, for PSMA-positive metastatic prostate cancer. The diagnostic counterparts — Netspot and Ga-68 PSMA-11 — are what light up the tumor on PET first. Then the lutetium-177 version delivers the radiation directly to those same sites.

What gets me about this is the precision argument. The whole framework is designed to spare healthy tissue by targeting the molecular signature of the disease itself. And the clinical data coming out of trials on 225-Ac-PSMA-617 — an alpha-particle therapy — showed 91 percent of patients experiencing a PSA decline, with a median survival of 15 months in metastatic castration-resistant prostate cancer. That's a meaningful number for a population that has already exhausted other options.

My read: nuclear medicine has been the quietest corner of imaging for a long time. That era is ending. If your department isn't already talking about radiopharmaceutical therapy capacity, it probably should be.

Staying in the prostate cancer space for a moment — because the imaging side of this story deserves its own attention. PSMA PET is increasingly the standard of care for staging and restaging prostate cancer, and the reason is accuracy. The scan detects small metastatic deposits that traditional CT and bone scan routinely miss. For a patient whose PSA is rising after surgery or radiation, that difference can completely change the treatment conversation.

The workflow is relatively fast — tracer injection, roughly an hour of uptake time, then scanning. For a disease that affects as many men as prostate cancer does, having a tool that guides precision therapy decisions this clearly is significant.

The clinical picture here is that PSMA PET and radioligand therapy are increasingly a paired system. The scan identifies the disease. The therapy follows the same target. That loop — image, confirm, treat — is what theranostics looks like in practice. Worth watching as lutetium-177 trials expand into earlier disease settings, including hormone-sensitive and biochemically recurrent prostate cancer. The pipeline is active.

Now, a shift in modality and population. New breast cancer screening guidelines are generating confusion, and if you work in breast imaging, you're probably already fielding the questions.

The updated guidance recommends digital breast tomosynthesis — 3D mammography — for women with dense breasts. That part is a step forward. What's generating friction is the recommendation against supplemental ultrasound and MRI for dense breast patients, at least as a routine add-on. That runs counter to what a lot of practices have been doing, and it runs counter to what a lot of patients have been told.

For the technologist running a busy mammo schedule, and for the radiologist fielding calls from referring physicians, this creates a real communication challenge. A patient who was told last year that her dense breasts warranted supplemental ultrasound is now being told the guidelines don't support that. The clinical relationship has to absorb that shift.

I want to be careful here — the article I'm working from is limited in detail, and I don't have the full guideline text or the organizations behind it in front of me. So I'm not going to overstate the specifics. What I will say is this: guideline confusion in screening programs has real consequences. Patients opt out. Referring physicians don't know what to order. Imaging departments get inconsistent requests. That's worth paying attention to regardless of where you land on the clinical debate.

Keep an eye on how professional societies respond to this one. The conversation is not settled.

And finally, a workforce story that didn't come from a radiology-specific outlet, but it absolutely belongs here. Last May — May 26th through the 30th — 163 caregivers at West Anaheim Medical Center in California went on strike. That group included licensed vocational nurses, respiratory therapists, surgical technicians, and imaging technologists.

I want to sit with that for a second. Imaging technologists were part of a multi-day strike action. That's not a headline you see often, and it matters. The workforce pressures that have driven nursing labor actions across the country over the past several years — staffing ratios, compensation, working conditions — those same pressures exist in imaging departments. They just don't make the news as often.

If you are in department leadership, this is a signal worth taking seriously. The technologist shortage is documented. Fellowship positions in multiple subspecialties are going unfilled. And now we're seeing imaging staff show up in labor actions alongside nursing colleagues. The pipeline problem and the retention problem are related.

My take: the field has spent a lot of energy talking about AI and workflow optimization. Less energy talking about whether the people running the equipment feel valued and supported. Those conversations need to happen in the same room.

That's the episode. Thank you for spending time with me today — it genuinely means a lot that you keep coming back. If Beyond the Scan has been useful to you, share it with a colleague. Subscribe wherever you listen. And find us at beyondthescan.io.

I'll be back in two weeks with more updates.